title: Novel strategy with gemcitabine for advanced pancreatic cancer.
abstract: 5-fluorouracil (5-FU) is widely used in chemotherapy for gastric and colorectal cancer, but gemcitabine (GEM), and not 5-FU, is approved as a standard drug for use in pancreatic cancer. Interindividual variation in the enzyme activity of the GEM metabolic pathway can affect the extent of GEM metabolism and the efficacy of GEM chemotherapy. Human equilibrative nucleoside transporter 1 (hENT1) is recognized as a major transporter of GEM into cells. In addition, a factor that activates hENT1 is the inhibition of thymidylate synthase (TS), one of the 5-FU metabolic enzymes; TS inhibition mediates depleting intracellular nucleotide pools, resulting in the activation of the salvage pathway mediated through hENT1. In this paper, the role of 5-FU in GEM-based chemotherapy for pancreatic cancer is discussed with special emphasis on enzymes involved in the 5-FU and GEM metabolic pathways and in the correlation between GEM responsiveness and the expression of 5-FU and GEM metabolic enzymes.
authors.affiliation: Department of Surgical Oncology, Gifu University Graduate School of Medicine, Yanagido, 1-1 Yanagido, Gifu 501-1194, Japan.
authors.forename: Shuji
authors.initials: S
authors.lastname: Komori
authors.forename: Shinji
authors.initials: S
authors.lastname: Osada
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Yoshida
references.citation: Mol Cancer Ther. 2002 Apr;1(6):371-6
references.pmid: 12477049
references.citation: J Clin Oncol. 2007 May 20;25(15):1960-6
references.pmid: 17452677
references.citation: Anticancer Drugs. 2002 Jan;13(1):75-85
references.pmid: 11914644
references.citation: J Clin Oncol. 2005 Jul 10;23(20):4532-7
references.pmid: 16002844
references.citation: Anticancer Res. 2008 Jan-Feb;28(1A):45-50
references.pmid: 18383823
references.citation: Cancer Res. 2002 Jun 15;62(12):3361-4
references.pmid: 12067974
references.citation: J Clin Oncol. 2006 Oct 10;24(29):4731-7
references.pmid: 16966686
references.citation: Oncogene. 2003 Oct 20;22(47):7524-36
references.pmid: 14576856
references.citation: Jpn J Cancer Res. 2000 Dec;91(12):1250-7
references.pmid: 11123423
references.citation: Mol Pharmacol. 2005 Jul;68(1):110-8
references.pmid: 15795320
references.citation: JAMA. 2007 Jan 17;297(3):267-77
references.pmid: 17227978
references.citation: Clin Cancer Res. 2003 Sep 15;9(11):4165-71
references.pmid: 14519641
references.citation: Pancreas. 2010 Nov;39(8):1284-92
references.pmid: 20944490
references.citation: Adv Exp Med Biol. 2000;486:287-90
references.pmid: 11783501
references.citation: Drug Resist Updat. 2002 Feb;5(1):19-33
references.pmid: 12127861
references.citation: Cancer Res. 1998 Oct 1;58(19):4349-57
references.pmid: 9766663
references.citation: Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):14036-40
references.pmid: 8943056
references.citation: Jpn J Clin Oncol. 2004 Oct;34(10):594-601
references.pmid: 15591457
references.citation: Cancer Res. 2000 Nov 1;60(21):6075-9
references.pmid: 11085530
references.citation: Neoplasia. 2009 Jul;11(7):637-50
references.pmid: 19568409
references.citation: Br J Cancer. 2007 Jul 16;97(2):145-51
references.pmid: 17595663
references.citation: Br J Cancer. 2007 Feb 12;96(3):457-63
references.pmid: 17224927
references.citation: CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
references.pmid: 19474385
references.citation: Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2095-100
references.pmid: 16609021
references.citation: J Mol Biol. 2001 Dec 7;314(4):765-72
references.pmid: 11733995
references.citation: JOP. 2010 Jul 05;11(4):317-20
references.pmid: 20601801
references.citation: Clin Exp Metastasis. 1998 Jan;16(1):43-9
references.pmid: 9502076
references.citation: Ann Oncol. 2006 May;17 Suppl 5:v7-12
references.pmid: 16807468
references.citation: Mol Cancer Ther. 2006 Jun;5(6):1387-95
references.pmid: 16818496
references.citation: J Clin Oncol. 2005 May 20;23(15):3509-16
references.pmid: 15908661
references.citation: Biochem Pharmacol. 1995 May 17;49(10):1419-26
references.pmid: 7763285
references.citation: J Clin Oncol. 1997 Jun;15(6):2403-13
references.pmid: 9196156
references.citation: Cancer Res. 1992 Aug 15;52(16):4306-12
references.pmid: 1643628
references.citation: Clin Cancer Res. 2004 Oct 15;10(20):6956-61
references.pmid: 15501974
references.citation: Oncology. 2006;70(5):366-77
references.pmid: 17179731
references.citation: Curr Med Chem Anticancer Agents. 2003 Mar;3(2):119-31
references.pmid: 12678906